Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization - Total: 2012-2020

Historic Depreciation & Amortization - Total for Ani Pharmaceuticals (ANIP) over the last 9 years, with Dec 2020 value amounting to $1.3 million.

  • Ani Pharmaceuticals' Depreciation & Amortization - Total rose 8.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $7.4 million for FY2024, which is 1.33% down from last year.
  • As of Q4 2020, Ani Pharmaceuticals' Depreciation & Amortization - Total stood at $1.3 million, which was up 8.33% from $1.2 million recorded in Q3 2020.
  • In the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization - Total ranged from a high of $1.3 million in Q4 2020 and a low of $200,000 during Q1 2016.
  • For the 3-year period, Ani Pharmaceuticals' Depreciation & Amortization - Total averaged around $966,667, with its median value being $1.1 million (2019).
  • Data for Ani Pharmaceuticals' Depreciation & Amortization - Total shows a peak YoY spiked of 300.00% (in 2019) over the last 5 years.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization - Total (Quarterly) stood at $200,000 in 2016, then spiked by 50.00% to $300,000 in 2017, then spiked by 166.67% to $800,000 in 2018, then spiked by 50.00% to $1.2 million in 2019, then grew by 8.33% to $1.3 million in 2020.
  • Its Depreciation & Amortization - Total stands at $1.3 million for Q4 2020, versus $1.2 million for Q3 2020 and $1.2 million for Q2 2020.